<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842074</url>
  </required_header>
  <id_info>
    <org_study_id>P110147</org_study_id>
    <secondary_id>2012-001988-78</secondary_id>
    <nct_id>NCT01842074</nct_id>
  </id_info>
  <brief_title>Desensitization With Bortezomib Before a Living Kidney Donation</brief_title>
  <acronym>VELDON</acronym>
  <official_title>Desensitization With Bortezomib Before a Living Kidney Donation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to study the role of bortezomib for desensitizing patients awaiting a
      living kidney donation who have a titer of Donor Specific anti human leucocyte antigen (HLA)
      Antibody (DSA) between 1000 and 3000 MFI with a pilot study of 10 patients recruited in 4
      hospital in FRANCE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to study the role of bortezomib for desensitizing patients awaiting a
      living kidney donation who have a titer of Donor Specific anti HLA Antibody (DSA) between
      1000 and 3000 MFI with a multicentre pilot study of 10 patients. The effect of bortezomib
      will be observed up to 6 month after bortezomib treatment prior to transplantation and 12
      month after transplantation if performed. The living kidney donation will be performed only
      if the DSA level drops below 1000 MFI which means an efficacy of the desensitization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Donor specific antibody (DSA) level below 1000MFI authorizing the living kidney donation</measure>
    <time_frame>up 6 months after bortezomib treatment and before transplantation</time_frame>
    <description>Bortezomib treatment should allow a decrease in DSA level below a threshold level authorizing the living kidney donation with minimal risk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative differences of the DSA titer ans antiHLA non DSA titer bortezomib treatment</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment 12 months after transplantation if performed, if not 6 month after the last bortezomib injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinical symptoms and anomalies</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anomalies at the standard blood tests</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anomalies at the total lymphocyte count and phenotyping</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of proteinuria and anomalies at the glomerular filtration rate</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of transplanted patients</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment 12 months after transplantation if performed, if not 6 month after the last bortezomib injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven acute rejection and chronic rejection</measure>
    <time_frame>12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed</time_frame>
    <description>Safety and efficacy of bortezomib treatment 12 months after transplantation if performed, if not 6 month after the last bortezomib injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Patients Awaiting a Living Kidney Donation</condition>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation</description>
    <arm_group_label>Bortezomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient between 18 and 70 years old

          -  awaiting a living kidney donation

          -  but with a least one DSA titer between 1000 MFI and 3000 MFI

        Exclusion Criteria:

          -  positive cell dependent cytotoxicity CM,

          -  DSA level above 3000 MFI

          -  and every condition that is a contre indication for bortezomib treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène François, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hôpitaux de Paris - Bicêtre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène François, MD, PhD</last_name>
    <phone>33(0)145212722</phone>
    <email>helene.francois@bct.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antoine DURRBACH, MD, PhD</last_name>
    <phone>33(0)145212771</phone>
    <email>antoine.durrbach@bct.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital</name>
      <address>
        <city>Le KREMLIN-BICETRE</city>
        <zip>94 275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène François, MD, PhD</last_name>
      <phone>33(0)145212722</phone>
      <email>helene.francois@bct.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Antoine Durrbach, MD, PhD</last_name>
      <phone>33(0)145212771</phone>
      <email>antoine.durrbach@bct.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Hélène François, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bortezomib</keyword>
  <keyword>desensitization</keyword>
  <keyword>living kidney transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

